AngioDynamics Gains Humana Medicare Advantage Coverage for NanoKnife System
AngioDynamics, Inc. (ANGO) announced that Humana updated its Medicare Advantage policy to cover NanoKnife Irreversible Electroporation procedures. Effective October 1, 2026, the updated policy applies medical necessity criteria under Local Coverage Determination L40205 for patients with eligible intermediate-risk prostate cancer and specific liver tumors. Shares of AngioDynamics traded down 4.39% to $10.90 following the announcement.
The policy change broadens insurance coverage across Humana's approximately 7 million Medicare Advantage members. This update follows prior reimbursement steps, including the implementation of Category I CPT billing codes on January 1, 2026, and regional coverage from Palmetto GBA on July 5, 2026. Although treatments will require prior authorization, increased payer alignment helps lower administrative obstacles for medical providers and eligible patients.
Going forward, key factors to monitor include additional coverage adoption by other major health insurers, actual procedure volume growth, and official financial guidance regarding the commercial impact of the expansion.
Key points
- Humana updated its Medicare Advantage policy to cover AngioDynamics' NanoKnife IRE for certain prostate and liver cancers, effective October 1, 2026.
- The policy change extends medical necessity criteria to approximately 7 million Humana Medicare Advantage members.
- Patients receiving the treatment will require prior authorization from Humana.
- The move follows Category I CPT billing codes introduced on January 1, 2026, and regional Medicare coverage effective July 5, 2026.
- Shares of AngioDynamics (ANGO) fell 4.39% to $10.90 in market trading.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the new Medicare Advantage coverage for AngioDynamics NanoKnife?
Humana updated its Medicare Advantage policy effective October 1, 2026, to cover NanoKnife IRE for eligible intermediate-risk prostate cancer and certain liver tumors under LCD L40205 criteria.
How many members does Humana Medicare Advantage have?
Humana has approximately 7 million Medicare Advantage members who are eligible under the updated coverage policy, subject to prior authorization.
When did the new Humana coverage for NanoKnife IRE take effect?
The coverage update for eligible prostate cancer and liver tumor treatments became effective on October 1, 2026.